Company news
Kala Bio, Inc. news in 2025
Kala Bio, Inc.'s news releases, calls and decks from 2025, newest first.
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
December 5, 2025
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
December 4, 2025
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
December 1, 2025
KALA BIO scraps development of eye disease drug after trial failure
September 29, 2025
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
September 29, 2025
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
September 2, 2025
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 8, 2025
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 6, 2025
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
July 9, 2025
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
July 7, 2025
KALA BIO to Present at Jefferies Global Healthcare Conference
May 29, 2025
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 31, 2025
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
February 26, 2025
KALA BIO Announces Chief Executive Officer Transition
February 11, 2025